M. Carrio et al., Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene, GENE THER, 6(4), 1999, pp. 547-553
We have evaluated the effectiveness of combining the different characterist
ics of retrovirus and adenovirus to apply the herpes simplex Virus thymidin
e kinase gene (HSVtk) and ganciclovir (GCV) treatment for gene therapy of p
ancreatic cancer. Transduction of NP-18 human pancreatic cells in culture b
y either the adenoviral vector (ADV/tk) or the retroviral vector (Rv/tk) fo
llowed by GCV treatment resulted in a GCV dose-dependent cytotoxic effect.
A bystander effect was determined both in NP-18 cultures and in xenogeneic
cell mixtures of NP-18 and PA317 cells. Studies in vivo indicated that the
effectiveness of tumor regression after HSVtk gene transfer and GCV treatme
nt was dependent first an the tumor size at the time of viral injection and
secondly, in large tumors, on the type of virus administered. The administ
ration of the viral combination (ADV/tk + vector producer cells VPC-Rv/tk)
was the best approach tested and resulted in a dramatic reduction in tumor
mass after 4 days of GCV treatment which was maintained for the treatment p
eriod. Remarkably, two animals presented a complete eradication of the tumo
r Thus, the HSVtk/GCV system when administered using a viral combination (A
DV/tk + VPC-Rv/tk), may be a promising suicide gene therapy for pancreatic
carcinomas.